Literature DB >> 20676123

Vasculitis syndromes: Not losing sight is the issue in GCA management.

Miguel A González-Gay, Vicente Rodríguez-Valverde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20676123     DOI： 10.1038/nrrheum.2010.119

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  BSR and BHPR guidelines for the management of giant cell arteritis.

Authors:  Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

2.  Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study.

Authors:  C Salvarani; G G Hunder
Journal:  Arthritis Rheum       Date:  2001-04

Review 3.  Epidemiology of giant cell arteritis and polymyalgia rheumatica.

Authors:  Miguel A Gonzalez-Gay; Tomas R Vazquez-Rodriguez; Maria J Lopez-Diaz; Jose A Miranda-Filloy; Carlos Gonzalez-Juanatey; Javier Martin; Javier Llorca
Journal:  Arthritis Rheum       Date:  2009-10-15

4.  Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients.

Authors:  Miguel A Gonzalez-Gay; Sonia Barros; Maria J Lopez-Diaz; Carlos Garcia-Porrua; Amalia Sanchez-Andrade; Javier Llorca
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

5.  How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?

Authors:  A A Achkar; J T Lie; G G Hunder; W M O'Fallon; S E Gabriel
Journal:  Ann Intern Med       Date:  1994-06-15       Impact factor: 25.391

6.  Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.

Authors:  M A González-Gay; R Blanco; V Rodríguez-Valverde; V M Martínez-Taboada; M Delgado-Rodriguez; M Figueroa; E Uriarte
Journal:  Arthritis Rheum       Date:  1998-08

7.  Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.

Authors:  C Salvarani; C Della Bella; L Cimino; P Macchioni; D Formisano; G Bajocchi; N Pipitone; M G Catanoso; G Restuccia; A Ghinoi; L Boiardi
Journal:  Rheumatology (Oxford)       Date:  2008-12-24       Impact factor: 7.580

8.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.

Authors:  Alfred D Mahr; Juan A Jover; Robert F Spiera; César Hernández-García; Benjamin Fernández-Gutiérrez; Michael P Lavalley; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2007-08

Review 9.  Neurologic aspects of giant cell (temporal) arteritis.

Authors:  R J Caselli; G G Hunder
Journal:  Rheum Dis Clin North Am       Date:  1993-11       Impact factor: 2.670

10.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.

Authors:  V M Martínez-Taboada; V Rodríguez-Valverde; L Carreño; J López-Longo; M Figueroa; J Belzunegui; E M Mola; G Bonilla
Journal:  Ann Rheum Dis       Date:  2007-12-17       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.